🦠 Cryptococcosis Treatment Algorithm Global Guidelines for Diagnosis and Management | Evidence-Based Recommendations Based on the Global Guideline for the Diagnosis and Management of Cryptococcosis (Lancet Infectious Diseases, 2024) 🧠 CNS Cryptococcosis HIV SOT Non-HIV/Non-SOT C. gattii Cryptococcoma 🔄 Disseminated Disease (Non-CNS/Non-pulmonary) 🫁 Pulmonary Disease Severe Mild With/Without Cryptococcoma 🩹 Direct Skin Inoculation Cutaneous infection…
Introduction Candida species are the predominant cause of fungal infections in patients treated in hospital settings, causing significant morbidity and mortality worldwide. This clinical practice guide summarises evidence-based recommendations from the European Confederation for Medical Mycology (ECMM) global guideline initiative, developed in cooperation with the International Society of Human and Animal Mycology (ISHAM) and the…
Emergomycosis is a systemic fungal mycosis caused by a novel dimorphic fungi called Emergomyces species. It is mainly seen in immunocompromised patients. The first case of Emergomycosis was identified in 1994 in Italy; however, the fungus was described in 1998. Disseminated Emergomycosis observed a case fatality rate of 48%. These fungi were initially classified as…
Introduction Candida auris is a pathogen that has emerged as a global threat in recent years. It is the first human pathogenic fungus subject to international health alerts. The reason behind these concerns are – Public Health England reported in 2017 that almost all the C auris in the UK are fluconazole-resistant. There is also…
The Fungus: Identification: It initially forms white colonies with a yellow back, which quickly becomes black. Conidia is rough, brownish-black, biseriate, and covers the entire vesicle. A key feature in diagnosing A. niger infection is the presence of calcium oxalate crystals on pathological examination. The presence of crystals can be taken as an indication of A niger…
Echinocandins are a class of antifungals that prevent glucan synthesis pathways necessary for fungal cell wall formation. Echinocanins are antifungals that are widely used in clinical practice.Three echinocandins are approved for clinical use – Caspofungin, Micafungin and Anidulafungin.A fourth echinocandin – Rezafungin is being developed. Some other antifungals (some in development) that act of fungal cell walls…
For FRCPath Microbiology, I consider the fungi highlighted in yellow are must-read. Grey highlighted ones – if you have time.
